|
|
Volumn 147, Issue 2, 2014, Pages 534-536
|
|
Combination of daclatasvir and sofosbuvir for hepatitis C genotypes 1, 2, and 3
a a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DACLATASVIR;
LEDIPASVIR;
RIBAVIRIN;
SOFOSBUVIR;
ANTIVIRAL RESISTANCE;
ANTIVIRAL THERAPY;
CLINICAL TRIAL (TOPIC);
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG SAFETY;
FOLLOW UP;
HEPATITIS C;
HEPATITIS C VIRUS GENOTYPE 1;
HEPATITIS C VIRUS GENOTYPE 2;
HEPATITIS C VIRUS GENOTYPE 3;
HUMAN;
MULTICENTER STUDY (TOPIC);
NONHUMAN;
NOTE;
PRIORITY JOURNAL;
SAMPLE SIZE;
SUSTAINED VIROLOGIC RESPONSE;
VIRUS RESISTANCE;
ANTIVIRAL AGENTS;
FEMALE;
HEPACIVIRUS;
HEPATITIS C, CHRONIC;
HUMANS;
IMIDAZOLES;
MALE;
URIDINE MONOPHOSPHATE;
VIRAL NONSTRUCTURAL PROTEINS;
|
|
EID: 84904677024
PISSN: 00165085
EISSN: 15280012
Source Type: Journal
DOI: 10.1053/j.gastro.2014.06.016 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|